Literature DB >> 127744

In vitro proliferative response of BALB/c mouse spleen cells stimulated with trinitrophenylated syngeneic spleen cells.

H Tokuyama.   

Abstract

Spleen cells from normal BALB/c mice showed in vitro proliferative response against hapten-conjugated syngeneic spleen cells. Trinitrophenylated (TNP) spleen cells were prepared by treating normal spleen cells with sodium 2,4,6-trinitrobenzenesulphonate (TNBS). Four-day cultures of TNP-labelled spleen cells incorporated 2.5-7.4 times more [3H]thymidine than similar cultures of untreated spleen cells. An obviously positive mixed lymphocyte reaction (MLR) by normal spleen cells against mitomycin C (MC) treated TNP-labeled syngeneic spleen cells was observed after 4 days of culture. The MLR to TNP-labelled syngeneic cells was inhibited in the presence of epsilon-TNP-L-lysine by 23-37%. The spleen cells from the mice injected intraperitoneally with TNP-labelled syngeneic spleen cells showed a higher MLR against TNP-labelled spleen cells than normal spleen cells. The sensitized spleen cells also showed an increased response to MC-treated spleen cells. These results suggest that normal spleen cells include cells which can recognize the hapten and new antigenic determinants introduced into syngeneic spleen by chemical modification.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 127744      PMCID: PMC1445988     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  13 in total

1.  The immune response against hapten-autologous protein conjugates in the mouse. I. Specificity of antibodies produced during the primary response against dinitrophenylated mouse serum albumin.

Authors:  B Rubin
Journal:  Eur J Immunol       Date:  1973-01       Impact factor: 5.532

2.  Specific inhibition of an anti-hapten immune response by chemical modifications of cells.

Authors:  D Naor; R I Mishell; L Wofsy
Journal:  J Immunol       Date:  1970-12       Impact factor: 5.422

3.  Lymphocyte transformation in contact sensitivity.

Authors:  A F Geczy; A Baumgarten
Journal:  Immunology       Date:  1970-08       Impact factor: 7.397

4.  Suppression of contact sensitivity by T cells in the mouse. I. Demonstration that suppressor cells act on the effector stage of contact sensitivity; and their induction following in vitro exposure to antigen.

Authors:  G L Asherson; M Zembala
Journal:  Proc R Soc Lond B Biol Sci       Date:  1974-11-05

5.  Lymphocyte transformation during dinitrochlorobenzene contact sensitization. An in vitro and in vivo evaluation of the primary immune response in man.

Authors:  A E Miller; W R Levis
Journal:  J Clin Invest       Date:  1973-08       Impact factor: 14.808

6.  Tolerance and contact sensitivity to DNFB in mice. II. Specific in vitro stimulation with a hapten, 2,4-dinitrobenzene sulfonic acid (DNB-SO3Na).

Authors:  P Phanuphak; J W Moorhead; H N Claman
Journal:  J Immunol       Date:  1974-02       Impact factor: 5.422

7.  Isogeneic lymphocyte interaction: recognition of self antigens by cells of the neonatal thymus.

Authors:  M L Howe; A L Goldstein; J R Battisto
Journal:  Proc Natl Acad Sci U S A       Date:  1970-10       Impact factor: 11.205

8.  Immunization of dissociated spleen cell cultures from normal mice.

Authors:  R I Mishell; R W Dutton
Journal:  J Exp Med       Date:  1967-09-01       Impact factor: 14.307

9.  THE INDUCTION OF AUTOIMMUNITY IN RABBITS FOLLOWING INJECTION OF HETEROLOGOUS OR ALTERED HOMOLOGOUS THYROGLOBULIN.

Authors:  W O WEIGLE
Journal:  J Exp Med       Date:  1965-02-01       Impact factor: 14.307

10.  Termination of acquired immunological tolerance to protein antigens following immunization with altered protein antigens.

Authors:  W O WEIGLE
Journal:  J Exp Med       Date:  1962-12-01       Impact factor: 14.307

View more
  1 in total

1.  T-cell-deficient mice produce more antihapten antibodies against syngeneic than against allogeneic erythrocyte conjugates.

Authors:  S Koskimies; O Mäkelä
Journal:  J Exp Med       Date:  1976-08-01       Impact factor: 14.307

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.